Pillar Biosciences
Massachusetts, United States · Biotechnology · 62 employees
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiV
Funding history
- Funding Round — $34.5M — May 2025
Recent signals
- Mar 03, 2026: Launched Pillar Biosciences launches the oncoReveal® Rapid AML Panel to enhance genomic insights for Acute Myeloid Leukemia.
- May 27, 2025: Raised $34.5M
- Sep 10, 2024: Pillar Biosciences Partners with AstraZeneca to Accelerate Liquid Biopsy Testing
See plans & pricing → Track Pillar Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.